Onyx Biotec Limited
IPO Details
Subscription
Lot Distribution
Reservation
Company Fin.
₹5(8.20%)
Premium (ELP)
Onyx Biotec Limited's successfully transitioned to public market status with its listing on NSE on Nov 22, 2024. The IPO mobilized 48,10,000 Shares in cumulative capital, including 48,10,000 Shares for corporate expansion.
The public offering was conducted within the price parameters of ₹58 to ₹61, with minimum investment lots of 2000 shares. subscription activity between Nov 13, 2024 and Nov 18, 2024 demonstrated market reception to the company's valuation and growth narrative.
The allotment process concluded on Nov 19, 2024, finalizing share distribution to successful bidders. The listing represents a transformational event, providing the company with enhanced market visibility, regulatory compliance framework, and access to diversified investor capital.
Investors can bid starting from the minimum lot size specified for this IPO, and only in multiples of that lot size. The table below shows the minimum and maximum investment for retail investors and HNIs in terms of lots, quantity, and amount.
Incorporated in May 2005, Onyx Biotec Limited is a pharmaceutical company focused on producing sterile water for injections and offering contract manufacturing services. It operates two facilities in Solan, Himachal Pradesh, where Unit I makes up to 6.38 lakh units of sterile water injections daily, and Unit II manufactures 40,000 units of dry powder injections and 26,667 units of dry syrup per day. The company caters to both domestic and international markets and serves over 100 clients, including well-known names like Hetero Healthcare, Mankind Pharma, Sun Pharma, and Reliance Life Sciences. Onyx Biotec is ISO 9001:2015 and ISO 14001:2015 certified and employed 175 people as of July 31, 2024.
Note : "Calculations for ‘Shares Offered’ and ‘Total Amount’ are based on the highest price in the issue price band."
- Expertise in Sterile Manufacturing: Recognized as a leading contract manufacturer with specialization in sterile formulations, delivering high-standard products in a highly regulated domain.
- Strong Quality Systems: Maintains robust quality assurance and quality control frameworks to ensure consistent product safety, compliance, and performance.
- Established Client Relationships: Long-standing partnerships with reputed clients drive repeat business and ensure stable revenue visibility.
- Regional Concentration: All manufacturing units are located in Solan, Himachal Pradesh, exposing operations to region-specific economic, political, and natural disruptions that could halt production.
- Operational Disruptions: Any slowdown or shutdown at the facilities may materially impact business continuity, financial performance, and cash flows.
- Quality & Delivery Challenges: Quality lapses or delays in product delivery may lead to order cancellations, contract breaches, reputational damage, and loss of client trust, thereby impacting future revenues.
- Sanjay Jain
- Naresh Kumar
- Fateh Pal Singh
Onyx Biotec Limited
Mas Services Limited